Saturday 17 October 2026 Export MTNB’s income statement to Excel — free account

Matinas Biopharma Holdings, Inc.

In the quarter to June 2026, EPS grew 79.9%, free cash flow grew 9.15% and total debt fell 54.5%, each against the same quarter a year earlier.

2.37 0.05 −2.07%

Follow MTNB

Alert me

Market cap: $2.4M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 1/9
Altman Z: −11.93
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.37

Revenue 4.28

Net Income (6.69)

Free Cash Flow (6.42)

Net Debt (0.81)

Current Ratio 0.85

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.13)

P/S ratio 0.24

P/B ratio 0.56

Past 5Y EPS Growth —

This Y EPS Growth 26.18%

Next Y EPS Growth 63.05%

Next Y revenue growth 0.18%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.55%

10-year low 10-year high

P/B against its own 10 years 76.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	7	4	1
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	16	8	4	1

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	3	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	55.69%	90.59%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(2.26%)	(40.31%)	(49.10%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	1	—	—	—	1
’22	—	1	1	1	3
’21	0	—	—	—	0
’20	—	—	0	0	0
’19	—	0	—	—	0
’18	0	0	—	—	0

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(1)	(2)	(7)
’24	(6)	(3)	(3)	(4)	(16)
’23	(4)	(2)	(4)	(5)	(15)
’22	(5)	(5)	(5)	(4)	(19)
’21	(5)	(1)	(6)	(4)	(15)
’20	(5)	(3)	(5)	(4)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(1)	(1)	(7)
’24	(6)	(3)	(3)	(4)	(16)
’23	(4)	(2)	(4)	(5)	(15)
’22	(5)	(5)	(5)	(4)	(20)
’21	(5)	(1)	(6)	(4)	(15)
’20	(5)	(3)	(5)	(4)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.50)	(3.10)	—	—	—
’25	(4.88)	(15.46)	(0.40)	(0.26)	(28.33)
’24	(20.09)	(17.19)	(12.72)	(24.72)	(74.72)
’23	(19.02)	(20.91)	(20.89)	(18.33)	(79.16)
’22	(20.68)	(20.47)	(18.88)	(12.56)	(72.60)
’21	(18.22)	(17.50)	(23.82)	(23.50)	(83.04)
’20	(19.73)	(21.28)	(20.54)	(23.90)	(85.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	20.55	50.50	16.20	28.50	24.50	33.40	21.65	5.50	0.48	0.48	Analyst estimates 2026–2028 Powerpack
	High	100.50	199.50	74.00	124.50	119.50	111.00	53.00	44.50	21.50	3.09
People
People	Employees	10	15	15	21	20	31	34	32	3	2
	Revenue/emp, $m	0.00	0.01	0.01	0.00	0.01	0.00	0.09	0.03	0.00	0.00
Income, $m
Income, $m	Revenue	—	0	0	0	0	0	3	1	—	—
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	(8)	(16)	(15)	(17)	(22)	(23)	(21)	(23)	(24)	(10)
	EBT margin, %	0.00	(10,583.43)	(12,178.63)	(19,345.99)	(14,179.91)	(70,554.55)	(658.63)	(2,093.25)	0.00	0.00
	Net income	(8)	(15)	(14)	(17)	(22)	(23)	(21)	(23)	(24)	(10)
	Depreciation	0	0	0	1	1	1	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	1.24	0.92	0.46	0.60	0.12	11.02	3.78	0.00	0.00
	Earnings	(10.50)	(18.00)	(107.61)	(89.69)	(85.46)	(83.04)	(72.60)	(79.16)	(74.72)	(28.33)
	Cash flow	(79.57)	(94.94)	(78.85)	(72.75)	(66.11)	(54.29)	(66.24)	(52.72)	(48.94)	(19.20)
	Capex	0.00	(7.81)	(4.09)	(2.09)	(0.02)	(0.93)	(3.08)	(0.75)	0.00	0.92
	Free cash flow	(79.57)	(102.75)	(82.94)	(74.85)	(66.13)	(55.22)	(69.32)	(53.47)	(48.94)	(18.29)
	Book value	92.98	88.50	123.31	170.63	242.60	187.21	126.68	66.41	23.38	13.23
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	P/S	—	49.99	18.59	86.42	52.87	74.02	2.42	0.76	—	—
	P/B	—	1.51	0.61	0.76	0.30	0.27	0.21	0.17	—	—
	EV/Sales	—	0.60	(40.79)	(23.53)	(121.12)	(185.62)	(6.61)	(2.46)	—	—
	EV/FCF	—	(0.01)	0.79	0.41	2.36	2.29	1.05	0.68	—	—
Cash, $m
Cash, $m	Operating cash flow	(6)	(11)	(10)	(14)	(17)	(15)	(19)	(15)	(16)	(7)
	Capex	—	(1)	(1)	0	0	0	(1)	0	—	0
	Free cash flow	(6)	(12)	(11)	(14)	(17)	(15)	(20)	(15)	(16)	(7)
Balance, $m
Balance, $m	Working capital	3	6	10	27	58	47	30	13	5	3
	Total debt	0	0	0	0	0	0	0	0	0	0
	Net debt	(4)	(7)	(12)	(28)	(59)	(50)	(29)	(14)	(7)	(4)
	Shareholders’ equity	7	11	16	33	64	52	37	19	8	5
Returns, %
Returns, %	ROA	(131.62)	(270.93)	(87.22)	(60.80)	(41.80)	(35.80)	(39.56)	(65.62)	(128.50)	(110.46)
	ROIC	(177.63)	(313.71)	(247.23)	(232.74)	(306.30)	(547.23)	(195.88)	(272.15)	(5,735.31)	(553.44)
	ROE	(336.12)	(1,089.33)	(264.65)	(103.29)	(52.23)	(42.12)	(47.11)	(82.11)	(180.73)	(176.54)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2023 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EIGRQ Eiger BioPharmaceuticals, Inc.	$2.6M	— (loss-making)	— (loss-making)	+41.06% (above 0%: growing)	n/m	+37.90% (above 0%: growing)	97.34%	(331.69%)	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
ELAB PMGC Holdings Inc.	$2.5M	— (loss-making)	—	+147.70% (above 0%: growing)	n/m	−44.95% (below 0%: shrinking)	29.52%	(292.91%)	Compare
NTBLQ Notable Labs, Ltd.	$2.4M	— (loss-making)	— (loss-making)	−96.88% (below 0%: shrinking)	n/m	−26.63% (below 0%: shrinking)	100.00%	(269,000.00%)	Compare
VBIO Valion Bio, Inc.	$2.4M	— (loss-making)	— (loss-making)	+15.87% (above 0%: growing)	n/m	−189.01% (below 0%: shrinking)	(99.32%)	0.00%	Compare
MTNB Matinas Biopharma Holdings, Inc.	$2.4M	— (loss-making)	— (loss-making)	+365,433.33% (above 0%: growing)	n/m	+9.15% (above 0%: growing)	0.00%	0.00%
BPTSY Biophytis SA Sponsored ADR	$2.4M	— (loss-making)	—	—	n/m	+53.15% (above 0%: growing)	0.00%	—	Compare
WINT Windtree Therapeutics, Inc.	$2.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+1.12% (above 0%: growing)	0.00%	0.00%	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$2.4M	—	—	+28.47%	—	−12.29%	29.52%	(292.91%)

All 614 Biotechnology stocks →

Matinas Biopharma Holdings, Inc. (MTNB) key facts

Matinas Biopharma Holdings, Inc. (MTNB) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, MTNB traded at $2.37, a market capitalization of $2.4 million.
Return on equity was −176.5% and debt-to-equity 0.00.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −11.93 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.